# 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry

> **NCT06395402** · PHASE2 · RECRUITING · sponsor: **University of Iowa** · enrollment: 120 (estimated)

## Conditions studied

- Neuroendocrine Tumors
- Neuroendocrine Tumor Grade 1
- Neuroendocrine Tumor Grade 2

## Interventions

- **DRUG:** Lutetium Lu 177 dotatate therapy

## Key facts

- **NCT ID:** NCT06395402
- **Lead sponsor:** University of Iowa
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-03
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06395402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06395402, "177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06395402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*